To account for setup and range uncertainties in IMPT, treatment plans can be robustly optimized by including error scenarios in the optimization. For oropharyngeal cancer patients, we derived 'robustness recipes' describing the error values of the included scenarios in minimax worst-case robust optimization that provide adequate CTV coverage for given population based distributions of systematic and random setup errors and proton range errors. The application of the recipe resulted in the desired coverage. Gaussian distributions of systematic and random setup errors and range errors (characterized by standard deviations of Σ, σ and ρ respectively) when used in minimax worst-case robust IMPT optimization.
Robustness recipes for minimax robust optimization in intensity-
1 Abstract Purpose: To derive a 'robustness recipe' giving the range (RR) and setup robustness (SR) settingsi.e. the error values -that ensure adequate CTV coverage in oropharyngeal cancer patients for given Gaussian distributions of systematic and random setup errors and range errors (characterized by standard deviations of Σ, σ and ρ respectively) when used in minimax worst-case robust IMPT optimization.
Methods and Materials:
For the analysis contoured CT scans of 6 unilateral and 6 bilateral patients were used. An IMPT plan was considered robust if for at least 98% of the simulated fractionated treatments 98% of the CTV volume received ≥ 95% of the prescribed dose. For fast assessment of the CTV coverage for given error distributions (i.e. different values of Σ, σ, and ρ) Polynomial Chaos methods were employed. Separate recipes were derived for the unilateral (ULC) and bilateral (BLC) cases using one patient from each group, and all 12 patients were included in the validation of the recipes. .34Σ−0.07σ+1.17 and RR=3% and 4% for ρ=1% and 2%, respectively. For the recipe validation 2 plans were generated for each of the 12 patients corresponding to Σ=σ=1.5 mm and ρ=0% and 2%. 22 plans had adequate CTV coverage in ≥98% of the simulated fractionated treatments, the remaining two had adequate coverage in 97.8% and 97.9%.
Conclusions:
Robustness recipes were derived that can be used in minimax robust optimization of IMPT treatment plans to ensure adequate CTV coverage for oropharyngeal cancer patients. Details)   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Introduction Intensity-Modulated Proton Therapy (IMPT) can potentially results in improved sparing of Organs At Risk (OARs) compared with Intensity-Modulated Radiotherapy (IMRT) using photon beams [1, 2] .
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However, the accuracy of IMPT dose delivery is highly susceptible to inaccuracies in the patient setup (characterized by a systematic setup error and a random setup error) and the anticipated proton range (known as the range error) [3] [4] [5] [6] . In traditional IMRT these uncertainties can be taken into account by margin recipes providing the needed margin around the Clinical Target Volume (CTV) that ensures adequate CTV coverage [7, 8] . Such recipes however cannot be applied to IMPT, because the underlying concept of Planning Target Volume is not applicable to proton therapy [9] .
To account for setup and range uncertainties in IMPT, robust treatment plans can be constructed by using 'minimax' optimization [10, 11] . In the 'minimax' method the worst-case value of the constraints and the objectives is optimized while simultaneously considering the dose distribution in the nominal scenario (without range or setup errors) and a limited number of error scenarios.
Typically these error scenarios correspond to an over-and underestimation of the proton range (i.e.
higher and lower range values without setup errors) and rigid shifts of the anatomy along each of the three principle axes (i.e. plus and minus shifts in the x, y and z directions without any range error), resulting in 9 total scenarios (1 nominal, 2 with range and 6 with setup errors). Since the minimax method disregards the probabilities of these scenarios it may lead to overly conservative treatment plans. Conversely, it does not consider the simultaneous occurrence of setup and range errors either and therefore may result in treatment plans that are not sufficiently robust.
Currently it is unknown what the robustness settings -i.e. the absolute values of the errors characterizing the 8 error scenarios -in the 'minimax' robust optimization methods should be in order to obtain a treatment plan that has a specified CTV coverage for a certain fraction of the patients in the presence of setup and range uncertainties. Therefore in this study we derived -for 
Material and Methods

Patient data
In this study, the CT and contour data of twelve previously treated oropharyngeal cancer patients (six unilateral and six bilateral) was used. Of these twelve patients, one unilateral case (ULC) and one bilateral case (BLC) were selected randomly to be used as training data set to derive the 'robustness recipes' and all 12 patients were used as test data set to validate them. Table 1 shows the patient characteristics.
Recipe derivation methodology
The approach to derive the 'robustness recipes' consisted of four steps. First, the RR was found that was needed to deal with different range errors. Second, treatment plans with different SR were made (in combination with the RR derived in the first step) using XXXX (see section on Treatment planning). The third step was to find for each treatment plan the largest systematic errors Σ that would still give adequate target coverage for different random setup errors σ. Last, the obtained data (i.e. the combinations of Σ and σ for different ρ values) was fit with quadratic polynomials, which together with the data itself form the recipes.
Treatment planning
Treatment plans were generated using XXXX [*], an in-house developed treatment planning system for fully automated, multi-criteria plan generation. Instead of using a single weighted-sum objective function, it optimizes the various defined objectives one-by-one according to priorities assigned by the user in the so-called 'wish-list' (lexicographic optimization). Wish-lists do in general also contain constraints, which always have to be met. Table 2 shows the wish-list used for all patients in this study. The automatic plan generation enabled the inclusion of a large number of treatment plans of consistently high, unbiased quality [*]. 8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   5 To account for setup and range errors XXXX uses the 'minimax' approach as described in the Introduction to make treatment plans robust [10,11 12, 13] . Setup errors were simulated by laterally shifting the pencil beams and range errors were simulated by scaling the values of the CT image.
To select optimal pencil beams, a proton beam resampling technique was used [*]. First, candidate pencil beams were randomly sampled from a very fine grid. Then the multi-criteria optimization was performed and at the end of the iteration the pencil beams with a low contribution were excluded from the next iteration. These three steps were repeated for each optimization iteration.
A dose of 66 Gy was prescribed to the high-dose CTV (primary tumor and positive neck levels) and a dose of 54 Gy to the low-dose CTV (elective neck levels), to be delivered simultaneously in 30 fractions [14] . CTV dose prescriptions were set to obtain for both CTVs at least 98% coverage with at least 95% of the prescribed dose (V 95% ≥ 98%) in all 9 scenarios and to keep the CTV volume receiving more than 107% of the prescribed dose below 2% (V 107% ≤ 2%). Proton energies that could be used ranged from 70 to 230 MeV and corresponding pencil beam widths ranged from 7 to 3 mm sigma (in air at the isocenter), respectively. A range shifter of 75 mm was used for superficial target regions, where it was assumed that this shifter could be inserted during the delivery of a treatment field.
Three beam directions with angles of 60, 180 and 300 degrees were used.
Treatment simulations
To quantify the robustness of a treatment plan we considered the D 98% of the CTV-high and CTV-low for different combinations of systematic and random setup error and range error distributions. The errors were all assumed to have Gaussian distribution with zero mean and standard deviations of Σ, σ and ρ, respectively. E.g. σ =2 mm means a random setup error with a Gaussian distribution with 2 mm standard deviation, while ρ= 2% means a Gaussian range error with a standard deviation of 2%. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   6 To simulate the effects of systematic and random setup errors, as well as range errors on the dose distribution of a fractionated treatment (assuming an infinite number of fractions), we used Polynomial Chaos Expansions (PCEs) [*] . PCEs are meta-models of the dose engine, which can be used to quickly calculate the expected dose distribution of a fractionated treatment for a given distribution of random setup errors and range errors for a specific systematic setup error. This method explicitly takes into account that proton dose distributions are not invariant under setup and range errors. For a detailed description of PCEs and validation experiments for its use in IMPT in oropharyngeal cancer patients we refer to XXXX [*] and the supplementary material. We simulated dose distributions of 100,000 fractionated treatments with different systematic setup and range errors for each combination of Σ, σ and ρ in order to obtain the distribution of the D 98% of the CTVhigh and CTV-low.
Study design
A treatment was considered robust (had an adequate CTV coverage) when for 98% of the simulated fractionated treatments (i.e. 98% of the patients) D 98% ≥ 95% of the prescribed dose held for both the CTV-high and the CTV-low. To establish the robustness settings for an adequately robust treatment we first determined the RR that is needed to handle a ρ of 1% or 2% without any setup error (for ρ=0% it was assumed that no RR was required). To this end, treatment plans with RR settings from 0% to 4%, in steps of 1%, were evaluated using the PCE-based simulations described above for ρ= 1% or 2% and Σ= σ= 0mm.
Next, plans were generated with the obtained RR settings combined with SR of 2, 3, 4, or 5mm.
Subsequently, we determined the combinations of systematic and random setup errors that still gave an adequate CTV coverage. For this evaluation seven random errors from σ = 0 to 3 mm in steps of 0.5 mm were tested. For each of them we determined the maximum Σ that would still result 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   7 in an adequate CTV coverage. Figure 1 shows a flowchart of the method. We first set an initial guess for Σ, then simulated fractionated treatments for the given Σ, σ and ρ, and finally determined the fraction of the treatments which had a D 98% of 95% of the prescribed dose. If this fraction was larger than 98% for both the CTV-high and CTV-low, Σ was increased, if it was less than 98% for either the CTV-high or CTV-low, or both, Σ was decreased. The minimum step size in Σ was 0.05 mm. At some point the previous systematic error did pass the coverage criterion, but the increased error did not.
In that case the previous systematic error was taken as the maximum systematic error that could be handled. This was done separately for the chosen ULC and BLC. It is also possible to construct the robustness recipe by searching for the robustness needed to handle a certain error instead of searching for the error that can be handled by a certain robustness. However, it is much more time consuming to construct a treatment plan than constructing a PCE for different errors and do the simulations, therefore the latter approach was chosen.
The obtained robustness settings were verified considering a specific combination of errors for all 12 patients in the test data set. For each patient we used Σ=σ=1.5 mm and ρ=0% or 2% [3] . The Σ and σ of 1.5mm correspond to residual setup errors due to bony anatomy deformation, in case of a daily alignment on vertebrae C1-C3 [15] . The SR settings were calculated by interpolation between the SR settings obtained earlier. For all patients, treatment plans were generated using the interpolated SR settings and the needed RR setting. Next, we simulated 100.000 fractionated treatments for each treatment plan and determined the fraction that received a D 98% of 95%.
To facilitate the usage of the recipe for systematic and random setup errors for which no data points are available, a least squares fit of the form of SR = aΣ 2 +bσ 2 +cΣ+dσ +e was done. Since the data suggested (see below) that the SR and RR were practically independent, the data over all ρ values was combined for this fit, thus the range error was not accounted for explicitly .   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 8
Results
We found that a 3% RR was needed for ρ = 1% and 2% to achieve an adequate CTV coverage for the ULC. For the BLC, a 3% RR was needed for ρ=1%, whereas a 4% RR was needed for ρ=2% (Table 3 ). Figure 2 shows the robustness recipe for different range errors. The data points indicate the maximum combination of systematic and random setup errors for which a certain SR provided adequate CTV coverage. These plots can be used to determine the SR needed, if the error distributions are known. For example, if we assume σ=1.5mm and Σ=1.3 mm and ρ=2%, a 4 mm SR is needed to achieve adequate coverage for the ULC.
Comparing the plots for different range errors, we see that changing the range error (and adjusting the RR accordingly) has a limited impact on the curves for the required SR. Figure 2 does not have data points the fits can be used, which completes the recipe.
To validate the recipe for all twelve patients for Σ=σ=1.5 mm and ρ=0% or 2%, the required SR was interpolated from the data in Figure 2 . The interpolated SR was 4.1 or 4.3 mm (unilateral patients) and 3.3 or 3.4 mm (bilateral patients), for a ρ=0% or 2% respectively. The RR used was 3% for ρ=1% (both unilateral and bilateral patients) and 3% (unilateral patients) or 4% (bilateral patients) for ρ=2%. 20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10
Discussion
To the best of our knowledge this is the first study establishing a recipe for calculating the error values for the scenarios to be included in minimax robust optimization that ensure an adequate CTV coverage for fractionated IMPT treatments in the presence of prior known systematic and random setup error and range error distributions. The recipe provides a practical method to bridge the gap between a straightforward minimax worst-case robust optimization and a probabilistic optimization.
We found a difference in robustness for unilateral and bilateral patients, where a treatment plan for a bilateral patient seemed to be more robust than a treatment plan for a unilateral patient with similar robustness settings. This suggests, that robustness settings need to be separately tuned for the various treatment sites and groups.
In this study we deemed a treatment to be adequate if in at least 98% of the simulated fractionated treatments the D 98% ≥ 95% of the CTV. In the past, other definitions were used for photon beam therapy. For example, van Herk et al. [7] considered a cumulative minimum CTV dose of 95% of the prescribed dose in 90% of the patients as adequate. In this study we chose the near minimum dose (D 98% ) following ICRU Report 83 [16] . Van Herk et al. [7] also used maximally tight synthetic dose distributions for the analyses. In this study we used realistic distributions, therefore it was decided to require adequate CTV coverage for 98% of treatments, instead of the 90% used by van Herk.
A limitation of this study was that both recipes were derived based on the CT and treatment plan data of a single patient from each group. In the validation experiments those patients appeared to be the 'worst cases' in their respective groups. For the other patients the CTV coverage was consistently higher than the required 98%. No particular reason was found why the training patients were the most sensitive to setup and range errors. It might be interesting to have a larger training data set. This would likely decrease the needed SR for the same setup errors. However this will most 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   11 likely also result in an inadequate tumor coverage for some patients. Future research will focus on gaining insight into inter-patient differences of the recipe and means of individualizing the recipe.
Another limitation of this study is the fact that the required SR and RR were determined independently, potentially resulting in non-optimal robustness recipes. Nevertheless, the required SR values for treatment plans with and without accounting for range errors were not substantially different (Figure 2) , which seems to suggest that setup and range robustness can indeed be handled independently. However, the required RR was determined in steps of 1%, therefore the recommended RR settings slightly overcompensate the range errors for which they were obtained (Table 3 ). The extra robustness may have compensated for interdependencies between setup and range errors.
The difference between the unilateral and bilateral patients seems consistent across patients, as the validation showed that a lower SR for the bilateral patients gives approximately the same CTV coverage as a higher SR for the unilateral patients ( Table 4 ). The mean fraction of the population with a D 98% of 95% for a 0% range error was 99.6% and 99.5% for the unilateral and bilateral patients respectively, not including the patients from the training data set. The bilateral patients, however, needed a higher range robustness setting and even with this higher setting a lower fraction of the simulated fractionated treatments received an adequate CTV coverage compared with the unilateral patients when considering only range errors ( Table 3 ).
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Conclusions
In this paper we developed for unilateral and bilateral oropharyngeal patients recipes for the error values that should be taken into account in minimax worst-case robust IMPT optimization to ensure robust CTV coverage in case of uncertainties in calculated proton ranges and systematic and random patient setup errors. The recipes for the patient groups were substantially different, as plans for bilateral patients were inherently more robust. A validation study showed that the recipes did indeed result in adequately robust plans .   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 64 65
Figure legends 
Figure2
Click here to download Figure: figure2.pdf
